2024 annual financial data
Inhibikase Therapeutics 2024 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -28,589,068 USD and net income was -27,519,886 USD.
Operating cash flow was -19,148,067 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -28,589,068 USD
- Net income
- -27,519,886 USD
- Operating cash flow
- -19,148,067 USD